• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Sale Of Alzheimer's Disease (AD) And Parkinson's Disease (PD) Medication Varies Between Each Country, For Example 55% Of AD Drug Sales Are Derived From The US Compared To 31% Of PD Drug Sales

Posted on: Tuesday, 19 December 2006, 09:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c47291) has announced the addition of Espicom Business Intelligence's CNS Drug Discoveries: Neurodegenerative Disorders Chapter to their offering.

This chapter of CNS Drug Discoveries focuses on the Alzheimer's disease and Parkinson's disease sectors of the market for neurodegenerative drugs.

Approximately US$6.6 billion was spent in 2005 on the symptomatic treatment of Alzheimer's disease (AD) and Parkinson's disease (PD). Although these neurodegenerative diseases only affect around 1% of the population their prevalence increases with age, thus these diseases are likely to become more commonplace due to patient demographics and become a greater burden on health care services.

Global Alzheimer's and Parkinson's market

In 2005, approximately 45% of AD/PD sales were derived from the US compared to 36% in Europe and the remainder (19%) in international markets including Japan. The sale of AD and PD medication varies between each country, for example 55% of AD drug sales are derived from the US compared to 31% of PD drug sales. The treatment of AD patients is dominated by the use of acetylcholinesterase inhibitors such as Aricept (Eisai), Exelon (Novartis) and Razadyne (Johnson & Johnson) although the use of the NMDA receptor antagonist Namenda/Ebixa (Forest/Lundbeck) is gaining acceptance, particularly in the treatment of moderate to severe AD. In contrast, PD patients are treated with a cocktail of drugs but predominantly with dopaminergic drugs such as Levodopa and/or dopamine agonists either as a monotherapy or in combination with catechol O-methyltransferase (COMT) inhibitors or monoamine oxidase (MAO) inhibitors.

Over the next six years, the author forecasts the market will undergo a new wave of treatments as the first disease-modifying agents (those that address the underlying cause of the diseases rather than the symptoms) are launched. These include Alzhemed (Neurochem), Flurizan (Myriad Genetics) and phenserine (Axonyx) for the treatment of AD and spheramine (Schering AG) for the treatment of PD.

Key questions answered in this chapter include:

-Who are the market leaders in the Alzheimer's market?

-What will the value of the Parkinson's market be in 2012?

-Will Eisai/Pfizer be able to defend their market-leading position with Aricept?

-What are the sales prospects for Lundbeck/Forest's Namenda?

-What impact will Phase III disease-modifying agents have on AD?

Content Outline:

NEURODEGENERATION EXECUTIVE SUMMARY THE FACTS PATIENT STATISTICS PATIENT MODEL DRUG GROWTH DRIVERS DRUG GROWTH RISKS/DAMPENERS GLOBAL AD/PD MARKET GLOBAL SALES SPLIT Market Share of PD players by sales (Dec 2005A) Market Share of AD players by sales (Dec 2012E) Market Share of PD players by sales (Dec 2012E) CURRENT AD TREATMENTS CURRENT PD TREATMENTS ANALYSIS OF LEADING BRANDS Acetylcholine Esterase (AChE) Inhibitors NMDA Antagonist Dopamine Agonists Monoaminoxidase (MAO) Inhibitors Catechol-O-Methyltransferase (COMT) Inhibitors GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012 NEW DRUGS IN R&DANALYSIS OF PHASE III DRUGS AD Agents Parkinson's Disease GLOBAL SALES FORECASTS OF PHASE III AD and PD DRUGS 2006 - 2012 ANALYSIS OF PHASE II DRUGS AD agents PD drugs COMPETITOR RATIO ANALYSIS PRODUCTS/DRUGS COMPETITOR RATIO ANALYSIS - COMPANIES DISCONTINUATION OF DRUGS NEURODEGENERATIVE APPENDIX 1 NEURODEGENERATIVE APPENDIX 2 NEURODEGENERATIVE APPENDIX 3 NEURODEGENERATIVE APPENDIX 4 NEURODEGENERATIVE APPENDIX 5 NEURODEGENERATIVE APPENDIX 6 NEURODEGENERATIVE GLOSSARY NEURODEGENERATIVE REFERENCES ACRONYMS

For more information visit http://www.researchandmarkets.com/reports/c47291

Source: Business Wire

More News in this Category